Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 999-1006

  Keats, Julian ^a   Micallef, Michelle ^b   Grebely, Jason ^b   Hazelwood, Susan ^a   Everingham, Hope ^a,c   Shrestha, Nikrant ^a,c   Jones, Tracey ^d,f   Bath, Nicky ^c   Treloar, Carla ^e   Dore, Gregory J ^b   Dunlop, Adrian ^a,f   Haber, Paul ^g   Carolyn, Day ^g   Gregory, Dore ^e   Tawil, Victor ^h   Krahn, Murray ⁱ   Loveday, Stuart ^j   Thein, Hla Hla ⁱ  

^a Drug Alcohol Clinical Services   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NSW Users and AIDS Association   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h Sage Building   (Australia)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j Hepatitis C Council of New South Wales   (Australia)

more..

Author keywords

Community support; HCV; Peer based support; People who inject drugs; Treatment

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSE ATTITUDE; NURSE PATIENT RELATIONSHIP; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; PATIENT COUNSELING; PATIENT EDUCATION; PEER GROUP; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; COMPLICATION; DRUG DEPENDENCE TREATMENT; HEPATITIS C; PATIENT ATTITUDE; PROGRAM EVALUATION; PSYCHOLOGY; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; AUSTRALIA; FEMALE; HEPATITIS C; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PEER GROUP; PROGRAM EVALUATION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84941809284     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.07.006     Document Type: Article

References (40)

1. Alavi M., Grebely J., Micallef M., Dunlop A.J., Balcomb A.C., Day C.A., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: The ETHOS study. Clinical Infectious Diseases 2013, 57(Suppl. 2):S62-S69. 10.1093/cid/cit305.
2. Alavi M., Raffa J.D., Deans G.D., Lai C., Krajden M., Dore G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 2013, 34(8):1198-1206. 10.1111/liv.12370.
3. Aspinall Esther J., Corson Stephen, Doyle Joseph S., Grebely Jason, Hutchinson Sharon J., Dore Gregory J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(Suppl 2):S80-S89.
4. Brunner N., Senn O., Rosemann T., Falcato L., Bruggmann P. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: A retrospective analysis. European Journal of Gastroenterology & Hepatology 2013, 25(11):1300-1307. 10.1097/MEG.0b013e32836140bb.
5. Butt Adeel A., Justice Amy C., Skanderson Melissa, Rigsby Michael O., Good Chester B., Kwoh Kent C. Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56(3):385-389.
6. Charlebois A., Lee L., Cooper E., Mason K., Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. Journal of Viral Hepatitis 2012, 19(12):836-842. 10.1111/j.1365-2893.2012.01648.x.
7. Crawford S., Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases 2013, 57(Suppl 2):S75-S79. 10.1093/cid/cit297.
8. Dimova Rositsa B., Zeremski Marija, Jacobson Ira M., Hagan Holly, Des Jarlais Don C., Talal Andrew H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2013, 56(6):806-816.
9. Grebely J., Knight E., Genoway K.A., Viljoen M., Khara M., Elliott D., et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 2010, 22(3):270-277.
10. Grebely J., Oser M., Taylor L.E., Dore G.J. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. Journal of Infectious Diseases 2013, 207(Suppl 1):S19-S25. 10.1093/infdis/jis928.
11. Grebely J., Raffa J.D., Lai C., Kerr T., Fischer B., Krajden M., et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. Journal of Viral Hepatitis 2011, 18(1):32-41. 10.1111/j.1365-2893.2010.01279.x.
12. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 2009, 16(5):352-358. 10.1111/j.1365-2893.2009.01080.x.
13. Grebely J., Tyndall M.W. Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV and AIDS 2011, 6(6):501-507. 10.1097/COH.0b013e32834bcb36.
14. Grebely Jason, Dore Gregory J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31(4):331-339.
15. Grebely Jason, Dore Gregory J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72. 10.1016/j.antiviral.2014.01.002.
16. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology & Hepatology 2013, 10(9):553-562. 10.1038/nrgastro.2013.107.
17. Hallinan R., Byrne A., Agho K., Dore G.J. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence 2007, 88(1):49-53.
18. Harris J., McElrath K. Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research 2012, 22(6):810-824. 10.1177/1049732311432718.
19. Harris K.A., Arnsten J.H., Litwin A.H. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. Journal of Addiction Medicine 2010, 4(1):20-26. 10.1097/ADM.0b013e3181add3de.
20. Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal 2013, 10:7. 10.1186/1477-7517-10-7.
21. Harris M., Rhodes T., Martin A. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science & Medicine 2013, 83:19-26. 10.1016/j.socscimed.2013.01.031.
22. Hellard Margaret, Sacks-Davis Rachel, Gold Judy Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
23. Iversen J., Grebely J., Topp L., Wand H., Dore G.J., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. Journal of Viral Hepatitis 2013, (Jul). [Epub ahead of print]. 10.1111/jvh.12129.
24. Lettmeier B., Muhlberger N., Schwarzer R., Sroczynski G., Wright D., Zeuzem S., et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. Journal of Hepatology 2008, 49(4):528-536. 10.1016/j.jhep.2008.04.021.
25. Lindenburg C.E., Lambers F.A., Urbanus A.T., Schinkel J., Jansen P.L., Krol A., et al. Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project. European Journal of Gastroenterology & Hepatology 2011, 23(1):23-31. 10.1097/MEG.0b013e328340c451.
26. Litwin A.H., Harris K.A., Nahvi S., Zamor P.J., Soloway I.J., Tenore P.L., et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2009, 37(1):32-40. 10.1016/j.jsat.2008.09.009.
27. Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 2008, 33(3):126-133. 10.1007/s10900-007-9083-3.
28. NCHECR Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales.
29. Nelson Paul K., Mathers Bradley M., Cowie Benjamin, Hagan Holly, Des Jarlais Don, Horyniak Danielle, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 2011, 378(9791):571-583.
30. Norman J., Walsh N.M., Mugavin J., Stoove M.A., Kelsall J., Austin K., et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal 2008, 5:8. 10.1186/1477-7517-5-8.
31. Rance J., Newland J., Hopwood M., Treloar C. The politics of place(ment): Problematising the provision of hepatitis C treatment within opiate substitution clinics. Social Science & Medicine 2012, 74(2):245-253. 10.1016/j.socscimed.2011.10.003.
32. Razavi H., Estes C., Pasini K., Gower E., Hindman S. HCV treatment rate in select European countries in 2004-2010. Journal of Hepatology 2013, 58:S22-S23. [Abstract].
33. Roose R.J., Cockerham-Colas L., Soloway I., Batchelder A., Litwin A.H. Reducing barriers to hepatitis C treatment among drug users: An integrated hepatitis C peer education and support program. Journal of Health Care for the Poor and Underserved 2014, 25(2):652-662. 10.1353/hpu.2014.0096.
34. Stein M.R., Soloway I.J., Jefferson K.S., Roose R.J., Arnsten J.H., Litwin A.H. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2012, 43(4):424-432. 10.1016/j.jsat.2012.08.007.
35. Strathdee S.A., Latka M., Campbell J., O'Driscoll P.T., Golub E.T., Kapadia F., et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases 2005, 40(Suppl 5):S304-S312. 10.1086/427445.
36. Sylvestre D.L., Zweben J.E. Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy 2007, 18(5):406-410. 10.1016/j.drugpo.2007.01.010.
37. Treloar C., Rance J., Bath N., Everingham H., Micallef M., Day C., et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy 2015, 26:992-998. 10.1016/j.drugpo.2015.01.005.
38. Treloar C., Rance J., Grebely J., Dore G.J. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug and Alcohol Dependence 2013, 133(2):529-534. 10.1016/j.drugalcdep.2013.07.023.
39. Volk M.L., Tocco R., Saini S., Lok A.S. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50(6):1750-1755. 10.1002/hep.23220.
40. Volk Michael L., Tocco Rachel, Saini Sameer, Lok Anna S.F. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50(6):1750-1755. [Erratum appears in Hepatology. 2010 Feb;51(2):725].